

Lourdes Vazquez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1528638/publications.pdf>

Version: 2024-02-01

132
papers

4,743
citations

116194

36
h-index

129628

63
g-index

138
all docs

138
docs citations

138
times ranked

6158
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>SARS-CoV-2</sc> reactive antibody detection after <sc>SARS-CoV-2</sc> vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. American Journal of Hematology, 2022, 97, 30-42.	2.0	52
2	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leukemia and Lymphoma, 2022, 63, 538-550.	0.6	8
3	Resistance to empirical β -lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study. Journal of Antimicrobial Chemotherapy, 2022, 77, 2017-2023.	1.3	5
4	Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH). Tj ETQq0 0 0 rgBT /Overlark 10 Tf 5	1.0	10
5	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology and Oncology, 2022, 15, 54.	6.9	26
6	Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Annals of Hematology, 2022, 101, 2053-2067.	0.8	7
7	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. American Journal of Transplantation, 2021, 21, 258-271.	2.6	11
8	The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. Mycoses, 2021, 64, 66-77.	1.8	11
9	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplantation, 2021, 56, 1281-1290.	1.3	3
10	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transplant Infectious Disease, 2021, 23, e13627.	0.7	5
11	Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study. Journal of Infection, 2021, 83, 306-313.	1.7	26
12	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. Journal of Fungi (Basel, Switzerland), 2021, 7, 4.	1.5	5
13	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. Medical Microbiology and Immunology, 2020, 209, 15-21.	2.6	8
14	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplantation cyclophosphamide. Transplant Infectious Disease, 2020, 22, e13206.	0.7	13
15	Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium. Blood Cancer Journal, 2020, 10, 75.	2.8	2
16	Risk factors and outcome of COVID-19 in patients with hematological malignancies. Experimental Hematology and Oncology, 2020, 9, 21.	2.0	119
17	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplantation, 2020, 55, 1347-1356.	1.3	9
18	Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. Enfermedades Infecciosas Y Microbiología Clínica, 2020, 38, 174-181.	0.3	22

#	ARTICLE	IF	CITATIONS
19	Polymorphisms within the <i>ARNT2</i> and <i>CX3CR1</i> Genes Are Associated with the Risk of Developing Invasive Aspergillosis. <i>Infection and Immunity</i> , 2020, 88, .	1.0	8
20	Micafungin as antifungal prophylaxis in non-transplanted haematological patients. <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 44-48.	0.5	3
21	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	1.3	2
22	Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC). <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 110-115.	0.5	3
23	Allogeneic stem cell transplantation for acquired pure red cell aplasia. <i>American Journal of Hematology</i> , 2019, 94, E294-E296.	2.0	9
24	Frequency, characteristics, and outcome of PTLD after allo-HSCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). <i>European Journal of Haematology</i> , 2019, 102, 465-471.	1.1	18
25	Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 757-761.	1.3	27
26	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. <i>Medical Oncology</i> , 2018, 35, 79.	1.2	15
27	Extracorporeal Photopheresis (ECP) for Acute and Chronic Graft versus Host Disease (GVHD): A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S309.	0.2	0
28	Resolution of Type IV Hypersensitivity After Bone Marrow Transplantation. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 190-190.	0.6	0
29	CCR6, IL7R, FAS AND MAdCAM-1 Single Nucleotide Polymorphisms are Associated With Higher Incidence of Infections in Allogeneic Stem-Cell Transplant From a Related Donor After a Reduced Intensity Conditioning Regimen: A Multicenter Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S382-S384.	0.2	0
30	Cutaneous Indeterminate Cell Histiocytosis of Donor Origin After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>American Journal of Dermatopathology</i> , 2017, 39, 696-699.	0.3	4
31	Reproduction of the atopic march in an adult after allogeneic bone marrow transplantation from an atopic sibling. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 190-191.	0.5	1
32	Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 438-444.	1.3	7
33	Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. <i>Revista Espanola De Quimioterapia</i> , 2017, 30, 103-117.	0.5	7
34	Biomarkers in Ocular Chronic Graft Versus Host Disease: Tear Cytokine- and Chemokine-Based Predictive Model. , 2016, 57, 746.		81
35	ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, e2016040.	0.5	22
36	Common Genetic Polymorphisms within NF- κ B-Related Genes and the Risk of Developing Invasive Aspergillosis. <i>Frontiers in Microbiology</i> , 2016, 7, 1243.	1.5	13

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw107.	0.4	36
38	GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. <i>Bone Marrow Transplantation</i> , 2016, 51, 1524-1526.	1.3	6
39	Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium. <i>Infection and Immunity</i> , 2016, 84, 643-657.	1.0	35
40	Hemorrhagic Cystitis in Haploidentical Hematopoietic STEM CELL Trasplant: Retrospective Study and Comparison with a NON-Haploidentical DONOR Transplant Group. <i>Blood</i> , 2016, 128, 3418-3418.	0.6	2
41	Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 370-375.	0.2	4
42	Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34 ⁺ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). <i>Transplant Infectious Disease</i> , 2015, 17, 221-233.	0.7	10
43	Gene Expression-Based Predictive Models of Graft Versus Host Disease-Associated Dry Eye. , 2015, 56, 4570.		42
44	Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodysplastic syndrome. <i>Leukemia Research</i> , 2015, 39, 828-834.	0.4	41
45	GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 121-126.	1.3	8
46	Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant. <i>British Journal of Haematology</i> , 2015, 169, 719-725.	1.2	37
47	Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2741-2744.	1.8	15
48	A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation. <i>Clinical Microbiology and Infection</i> , 2015, 21, e1-e3.	2.8	90
49	Serum Galactomannan Versus a Combination of Galactomannan and Polymerase Chain Reaction-Based Aspergillus DNA Detection for Early Therapy of Invasive Aspergillosis in High-Risk Hematological Patients: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 405-414.	2.9	133
50	Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. <i>Bone Marrow Transplantation</i> , 2015, 50, 274-281.	1.3	18
51	An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3142-3142.	0.6	0
52	Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1632-1637.	1.7	26
53	Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. <i>Hematology Reports</i> , 2014, 6, 5654.	0.3	4
54	Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. <i>Annals of Hematology</i> , 2014, 93, 299-307.	0.8	38

#	ARTICLE	IF	CITATIONS
55	Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. <i>Bone Marrow Transplantation</i> , 2014, 49, 684-690.	1.3	46
56	ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1745-1753.	0.8	33
57	Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome. <i>Blood</i> , 2014, 124, 1165-1165.	0.6	0
58	To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors. <i>European Journal of Haematology</i> , 2013, 91, 448-455.	1.1	28
59	Fatal disseminated <i>Scedosporium prolificans</i> infection initiated by ophthalmic involvement in a patient with acute myeloblastic leukemia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 375-378.	0.8	8
60	Chronic graft-versus-host disease of the kidney in patients with allogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2013, 91, 129-134.	1.1	42
61	Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. <i>Haematologica</i> , 2013, 98, 437-443.	1.7	69
62	The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycophenolate. <i>Haematologica</i> , 2013, 98, 526-532.	1.7	30
63	Treatment of invasive fungal infections in high-risk haematological patients: what have we learnt in the past 10 years?. <i>Revista Espanola De Quimioterapia</i> , 2013, 26, 378-86.	0.5	5
64	Effect of Posaconazole on Cyclosporine Blood Levels and Dose Adjustment in Allogeneic Blood and Marrow Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6422-6424.	1.4	22
65	Demodicidosis simulating acute graft-versus-host disease after allogeneic stem cell transplantation in one patient with acute lymphoblastic leukemia. <i>Transplant Infectious Disease</i> , 2012, 14, 387-390.	0.7	16
66	Dectin-1 and DC-SIGN Polymorphisms Associated with Invasive Pulmonary Aspergillosis Infection. <i>PLoS ONE</i> , 2012, 7, e32273.	1.1	126
67	Update on fungemia in oncology and hematology. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 42-47.	0.3	1
68	Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. <i>Haematologica</i> , 2011, 96, 1231-1235.	1.7	118
69	Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Clinical Microbiology and Infection</i> , 2011, 17, 1-24.	2.8	39
70	Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs. <i>Bone Marrow Transplantation</i> , 2011, 46, 1035-1036.	1.3	9
71	Effect of vitamin D treatment in chronic GVHD. <i>Bone Marrow Transplantation</i> , 2011, 46, 1395-1397.	1.3	21
72	Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. <i>Expert Review of Hematology</i> , 2011, 4, 9-16.	1.0	16

#	ARTICLE	IF	CITATIONS
73	Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms. Bone Marrow Transplantation, 2011, 46, 612-614.	1.3	17
74	Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant. Bone Marrow Transplantation, 2011, 46, 1487-1488.	1.3	1
75	Long-Term Reversibility of Renal Dysfunction Associated to Light Chain Deposition Disease with Bortezomib and Dexamethasone and High Dose Therapy and Autologous Stem Cell Transplantation. Clinics and Practice, 2011, 1, 205-208.	0.6	7
76	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica, 2010, 95, 1176-1182.	1.7	63
77	The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. European Journal of Haematology, 2010, 84, 266-270.	1.1	9
78	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. American Journal of Hematology, 2010, 85, 290-293.	2.0	2
79	Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation. Clinical and Experimental Dermatology, 2009, 34, e778-e781.	0.6	16
80	Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study. Biology of Blood and Marrow Transplantation, 2009, 15, 512-516.	2.0	7
81	Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2009, 15, 1331-1336.	2.0	13
82	Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. Medicina Clínica, 2008, 131, 441-446.	0.3	11
83	Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy. Biology of Blood and Marrow Transplantation, 2008, 14, 1163-1171.	2.0	85
84	The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2008, 14, 1288-1297.	2.0	53
85	Update on pulmonary infections in patients with hematologic malignancies and hematopoietic stem cell recipients. Enfermedades Infecciosas Y Microbiología Clínica, 2008, 26, 58-71.	0.3	0
86	R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica, 2008, 93, 1829-1836.	1.7	158
87	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. Journal of Clinical Oncology, 2008, 26, 577-584.	0.8	213
88	Update on viral infections in immunocompromised patients. Enfermedades Infecciosas Y Microbiología Clínica, 2007, 25, 2-11.	0.3	6
89	Severe Infections after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Comparison of Cord Blood Transplantation with Peripheral Blood and Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 734-748.	2.0	180
90	Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD). Biology of Blood and Marrow Transplantation, 2006, 12, 936-941.	2.0	36

#	ARTICLE	IF	CITATIONS
91	Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2006, 108, 2928-2936.	0.6	129
92	Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. <i>Bone Marrow Transplantation</i> , 2006, 37, 337-338.	1.3	15
93	Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. <i>Leukemia</i> , 2006, 20, 542-545.	3.3	81
94	Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 402-409.	3.3	85
95	Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability. <i>Experimental Hematology</i> , 2005, 33, 935-943.	0.2	10
96	CD34 ⁺ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 177-183.	0.6	24
97	Long-term Immune Recovery of Patients Undergoing Allogeneic Stem Cell Transplantation: A Comparison with Their Respective Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 354-361.	2.0	13
98	Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 437-447.	2.0	26
99	<i>Blastoschizomyces capitatus</i> Infection in Patients with Leukemia: Report of 26 Cases. <i>Clinical Infectious Diseases</i> , 2004, 38, 335-341.	2.9	108
100	Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 33, 183-187.	1.3	21
101	Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 33, 579-587.	1.3	6
102	Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1103-1103.	0.6	0
103	Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. <i>Annals of Hematology</i> , 2003, 82, 80-82.	0.8	86
104	Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. <i>Blood</i> , 2003, 101, 4695-4700.	0.6	126
105	Impact of CD34 ⁺ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003, 102, 1108-1113.	0.6	100
106	Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 79-88.	1.3	58
107	Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. <i>British Journal of Haematology</i> , 2002, 116, 475-482.	1.2	200
108	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. <i>Leukemia</i> , 2002, 16, 1423-1431.	3.3	103

#	ARTICLE	IF	CITATIONS
109	Mucormycosis diseminada en una paciente con leucemia mieloblástica aguda. <i>Actas Dermo-sifiliográficas</i> , 2001, 92, 154-157.	0.2	0
110	Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2001, 113, 161-171.	1.2	83
111	Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. <i>Transplant Infectious Disease</i> , 2001, 3, 44-46.	0.7	48
112	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 438-446.	1.2	100
113	Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. <i>British Journal of Haematology</i> , 2000, 109, 658-660.	1.2	18
114	Cerebral toxoplasmosis and Guillain-Barré syndrome after allogeneic peripheral stem cell transplantation. <i>Transplant Infectious Disease</i> , 2000, 2, 145-149.	0.7	18
115	Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 1229-1230.	1.3	23
116	Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. <i>Bone Marrow Transplantation</i> , 2000, 25, 217-218.	1.3	24
117	Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. <i>British Journal of Haematology</i> , 1999, 104, 695-705.	1.2	40
118	Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 901-905.	1.3	31
119	Factors that influence long-term hematopoietic function following autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 289-293.	1.3	17
120	Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 1279-1283.	1.3	67
121	Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. <i>Transfusion</i> , 1998, 38, 385-391.	0.8	78
122	Rhabdomyolysis associated with septicemia after autologous bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 95-95.	1.3	10
123	BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. <i>Bone Marrow Transplantation</i> , 1997, 20, 451-458.	1.3	134
124	Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 1997, 74, 79-82.	0.8	10
125	Sequential intravenous-oral ciprofloxacin plus amoxicillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. <i>Hematology and Cell Therapy</i> , 1997, 39, 223-227.	0.7	8
126	A randomized study comparing the effect of GM-CSF and G-CSF on immune reconstitution after autologous bone marrow transplantation. <i>British Journal of Haematology</i> , 1996, 94, 140-147.	1.2	19

#	ARTICLE	IF	CITATIONS
127	Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation. European Journal of Haematology, 1996, 56, 181-183.	1.1	9
128	Iron metabolism and fungal infections in patients with haematological malignancies.. Journal of Clinical Pathology, 1995, 48, 223-225.	1.0	53
129	Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. British Journal of Cancer, 1993, 68, 1227-1231.	2.9	45
130	Complex formation between protein c inhibitor and tissue plasminogen activator during thrombolytic therapy. Fibrinolysis, 1993, 7, 308-315.	0.5	6
131	Activated protein C:1-antitrypsin (APC:1AT) complex as a marker for diagnosis of prethrombotic states. Thrombosis Research, 1992, 66, 499-508.	0.8	15
132	Unexpectedly high toxicity of MACOP-B in young patients with low grade lymphoma. American Journal of Hematology, 1991, 38, 75-76.	2.0	1